美国FDA公开会议:确定多组分生物标志物的概念和术语

相关实验视频

Updated: Jul 16, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Abena S Agyeman¹, Abbas Bandukwala², Khaled Bouri³

¹Division of Pharmacology & Toxicology-Rare Diseases, Pediatrics, Urologic & Reproductive Medicine, Office of New Drugs (OND), Center for Drug Evaluation & Research (CDER), US FDA, Silver Spring, MD 20993, USA.

Biomarkers in medicine

|September 15, 2023

概括

美国食品和药物管理局 (FDA) 举办了一场研讨会,以标准化多组分生物标志物的术语. 这一倡议旨在改善沟通,并应对各种应用中的挑战.

科学领域:

生物标志物发现和开发
监管科学监管科学
翻译医学是一种翻译医学.

背景情况:

多组分生物标志物越来越多地被用于各种科学领域.
有效的沟通和标准化的术语对于它们的一致应用至关重要.
美国食品和药物管理局 (FDA) 观察了各种用途,并确定了这些生物标志物的常见问题.

研究的目的:

收集关于多元组分生物标记物的基本术语的反.
在FDA内讨论生物标志物的各种应用.
确定共同的挑战,并为多组件生物标志物建立首选的术语.

主要方法:

美国FDA召开了一个虚拟公共研讨会.
主题演讲和背景演讲讨论了研讨会的目标.
案例研究说明了FDA全局和外部对多组分生物标志物的经验.
专家小组讨论的重点是共同的主题,挑战和术语.

主要成果:

获得了关于多元组件生物标志物的有效沟通术语的反.
在FDA讨论了生物标志物的不同用途.
确定了与使用多组分生物标志物相关的常见问题和挑战.
建立了一个关于术语和使用的共识的初步基础.

结论:

标准化术语对于多组件生物标志物的有效沟通至关重要.
应对共同的挑战可以促进更广泛,更一致的生物标志物应用.
研讨会启动了在监管和科学界建立共识的过程.

关键词:

这些概念是概念的概念.定义的定义定义的定义.多元组件生物标志物术语术语术语的使用术语.

更多相关视频

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Published on: July 11, 2014

Identifying Per- and Polyfluorinated Chemical Species with a Combined Targeted and Non-Targeted-Screening High-Resolution Mass Spectrometry Workflow

Identifying Per- and Polyfluorinated Chemical Species with a Combined Targeted and Non-Targeted-Screening High-Resolution Mass Spectrometry Workflow

Published on: April 18, 2019

相关概念视频

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...